MannKind Corporation (NASDAQ:MNKD) is one of the popular penny stocks on Robinhood to buy. On March 11, MannKind Corporation (NASDAQ:MNKD) CEO Michael Castagna and CFO Chris Prentiss presented at the Barclays 28th Annual Global Healthcare Conference in Miami. The executives walked analysts through the company’s evolution from a single-revenue inhaled insulin business into a diversified, commercial-stage specialty pharma company. They also outlined what they expect to drive the next phase of growth.
According to the presentation, the most pressing near-term catalyst is the United Therapeutics, or UT, partnership, which had recently drawn market concern. Castagna addressed this directly, noting that following a meeting with UT, the company received reassurance that Tyvaso DPI remains central to UT’s future growth plans. The CEO added that MannKind has since learned it will be the primary, not backup, supplier for Tyvaso DPI. This means the minimum revenue floor under the supply agreement will be meaningfully higher than originally modeled.
Castagna also confirmed that MannKind and UT are collaborating on a second undisclosed compound. As part of the deal, MannKind will earn a 10% royalty on that product as well if and when it receives FDA approval.
The presentation detailed that MannKind completed its $360 million acquisition of scPharmaceuticals in October 2025. As such, FUROSCIX, a treatment for fluid overload in chronic heart failure and chronic kidney disease patients, is now part of the company’s products. This opens a new cardiometabolic business unit alongside MannKind’s existing orphan lung division, the CEO noted.
FUROSCIX generated $70 million in revenue in 2025, and management believes the $110-$120 million revenue target tied to the deal’s contingent value right is achievable in 2026. Analysts had previously modeled peak sales at $500 million, but Castagna called that figure a starting point, not a peak.
MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company that develops and commercializes treatments for diabetes and lung diseases. Its main product is Afrezza, an inhaled insulin therapy for adults with type 1 and type 2 diabetes, and it also co-develops Tyvaso DPI for pulmonary arterial hypertension.
While we acknowledge the potential of MNKD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
